By Counterforce Health Team in Vitrakvi (larotrectinib) —

Renewing Vitrakvi (Larotrectinib) Approval with Humana in Texas: Timeline, Documentation, and Bridge Options

Answer Box: Renewing Vitrakvi with Humana in Texas

Humana Medicare requires prior authorization renewal for Vitrakvi (larotrectinib) every 6-12 months. Submit renewal 2-4 weeks before expiration with updated imaging showing response/stable disease, oncology notes, and liver function tests. If approval lapses, request a 31-day emergency supply under Humana's transition policy while pursuing expedited renewal. Texas allows external review through an Independent Review Organization if denied.

First step today: Check your current PA approval letter for the exact end date and contact your oncologist to schedule renewal documentation.

Table of Contents

  1. Renewal Triggers: When to Start the Process
  2. Evidence Update: What Documentation You Need
  3. Renewal Packet: Must-Include Documents
  4. Timeline: Submission and Decision Windows
  5. If Coverage Lapses: Bridge Options
  6. Annual Changes: What to Re-verify
  7. Personal Tracker Template
  8. Appeals Process in Texas
  9. FAQ: Common Renewal Questions

Renewal Triggers: When to Start the Process

Check Your Current Authorization Status

Your Vitrakvi approval letter from Humana contains critical dates. Look for:

  • Authorization end date (typically 6-12 months from approval)
  • Number of cycles approved (if applicable)
  • Renewal requirements listed in the approval language
Tip: Set a calendar reminder 6-8 weeks before your authorization expires to begin gathering renewal documents.

Signs You Should Start Early

Start the renewal process immediately if:

  • Your current authorization expires within 60 days
  • Recent imaging shows any change in tumor status
  • You've had dose modifications due to side effects
  • Your oncologist has changed or you've switched treatment centers
  • Humana has updated their formulary or PA requirements

According to Humana's Medicare prior authorization guidelines, standard PA decisions take up to 14 calendar days, with possible 14-day extensions if additional information is needed.

Evidence Update: What Documentation You Need

Response to Therapy Documentation

Your renewal must demonstrate ongoing clinical benefit. Include:

Imaging Results (most critical):

  • Latest CT/MRI with RECIST 1.1 assessment (complete response, partial response, stable disease)
  • Comparison to baseline and previous scans
  • Explicit statement: "No radiologic progression" and "no new lesions"
  • Percentage change in target lesion measurements

Clinical Status:

  • ECOG performance status
  • Symptom improvement or stability
  • Quality of life measures
  • Any tumor-related complications resolved or controlled

Adverse Events and Safety Monitoring

Document that treatment remains tolerable and safe:

  • Liver function tests (ALT, AST) per FDA label requirements
  • Neurologic assessments (dizziness, fatigue monitoring)
  • Any dose modifications and rationale
  • Statement that "no toxicity requires permanent discontinuation"

Adherence Documentation

Include evidence of:

  • Prescription fill history from pharmacy
  • Patient-reported adherence
  • Any barriers to adherence addressed

Renewal Packet: Must-Include Documents

Core Documentation Checklist

Document Purpose Source
Updated oncology note Current clinical status Your oncologist
Latest imaging report Tumor response assessment Radiology department
Lab results (LFTs) Safety monitoring Lab/clinic
Original NTRK fusion report Confirms ongoing indication Molecular pathology lab
Prescription history Demonstrates adherence Pharmacy records
Previous PA approval letter Reference for renewal Your files

Medical Necessity Letter Structure

Your oncologist should include:

  1. Patient identification and diagnosis
  2. NTRK fusion status with lab method
  3. Disease status: metastatic/unresectable confirmation
  4. Treatment history: prior therapies tried/failed
  5. Current response: imaging dates and RECIST assessment
  6. Duration of benefit: months on Vitrakvi with response/stable disease
  7. Safety profile: manageable toxicity, appropriate monitoring
  8. Medical necessity statement: "Continuation of Vitrakvi is medically necessary for ongoing disease control"

Timeline: Submission and Decision Windows

Optimal Submission Timeline

  • 8 weeks before expiration: Schedule imaging and lab work
  • 6 weeks before: Oncology appointment for renewal assessment
  • 4 weeks before: Submit complete renewal packet to Humana
  • 2 weeks before: Follow up on PA status if no decision received

Humana Decision Timeframes

According to Humana's 2026 PA commitments:

  • Electronic submissions: Decision within 1 business day for 95% of complete requests
  • Standard requests: Up to 14 calendar days
  • Expedited requests: Within 72 hours if delay could jeopardize health

Submission Methods

Preferred: Electronic prior authorization through Humana's provider portal

Alternative: Fax using plan-specific PA forms (verify current fax number with Humana)

If Coverage Lapses: Bridge Options

Humana's Transition Policy

If your PA expires before renewal is approved, you may be eligible for temporary coverage under Humana's Medicare Transition Policy:

Emergency Supply: Up to 31 days of Vitrakvi while PA renewal is processed, if:

  • You're continuing an established therapy
  • Interruption would jeopardize your health
  • PA or appeal is actively pending

How to Request: Have your pharmacy contact Humana's pharmacy help line and request an "emergency supply" while PA is under review.

CenterWell Specialty Pharmacy Support

CenterWell Specialty Pharmacy can help coordinate:

  • PA renewal submissions
  • Bridge therapy requests
  • Refill timing to prevent gaps
  • Clinical support during transitions

Manufacturer Support

Bayer's TRAK Assist program provides:

  • Bridge supplies during PA processing
  • $0 copay program for eligible commercial patients
  • PA submission assistance
  • Appeals support

Contact: Verify current program details with your oncologist or at the manufacturer's official website.

Annual Changes: What to Re-verify

Formulary Updates

Each January, check if Vitrakvi's status has changed:

  • Tier placement: Use Humana's drug list tool
  • Prior authorization requirements: May be added, removed, or modified
  • Quantity limits: Could be adjusted
  • Step therapy: New requirements may be implemented

Plan Design Changes

Review your Summary of Benefits for:

  • Specialty tier coinsurance changes
  • Out-of-pocket maximum adjustments
  • Preferred pharmacy network updates

New Clinical Guidelines

Stay informed about:

  • Updated NCCN guidelines for NTRK inhibitors
  • New FDA safety communications
  • Emerging resistance patterns or monitoring recommendations

Personal Tracker Template

Key Dates to Track

  • Current PA expiration date: ___________
  • Next imaging scheduled: ___________
  • Last LFT results date: ___________
  • Renewal submission target: ___________
  • Follow-up call date: ___________

Response Documentation

  • Baseline tumor measurements: ___________
  • Best response achieved: ___________
  • Current response status: ___________
  • Months on treatment: ___________

Contact Information

  • Oncologist office PA coordinator: ___________
  • Humana member services: ___________
  • CenterWell Specialty Pharmacy: ___________
  • TRAK Assist program: ___________

Appeals Process in Texas

If Renewal is Denied

Internal Appeal (first step):

  • File within 60 days of denial notice
  • Submit via Humana's member portal or written request
  • Include updated clinical documentation
  • Request expedited review if delay risks health

External Review (if internal appeal fails):

  • Texas law provides Independent Review Organization (IRO) review
  • File within 4 months of final internal denial
  • IRO decision is binding on Humana
  • No cost to patient

Texas Department of Insurance assistance:

  • Consumer hotline: 1-800-252-3439
  • IRO information line: 1-866-554-4926
  • Online resources at [TDI website](verify with the source linked below)

When to Request Expedited Review

Request expedited processing if:

  • You're currently responding to Vitrakvi
  • Delay could cause disease progression
  • You have limited treatment alternatives
  • Clinical status is deteriorating

FAQ: Common Renewal Questions

Q: How long does Humana typically approve Vitrakvi renewals? A: Most oncology specialty drugs receive 6-12 month approvals. The exact duration depends on your response status and plan-specific policies.

Q: What if my imaging shows slight tumor growth? A: Document that changes don't meet RECIST 1.1 criteria for progression. Stable disease (less than 20% growth) typically supports continuation.

Q: Can I switch from CenterWell to my local specialty pharmacy? A: Check your plan's preferred pharmacy requirements. Some Humana plans require specialty drugs to be filled through CenterWell.

Q: What if my oncologist leaves the practice? A: Ensure medical records transfer includes your NTRK testing results and treatment history. The new oncologist will need this for renewal documentation.

Q: Does Texas Medicaid cover Vitrakvi differently than Humana Medicare? A: Yes, Medicaid has separate PA processes. This guide focuses on Humana Medicare Advantage and Part D plans.

Q: How do I know if my plan requires step therapy for renewals? A: Check your current PA approval letter and Humana's formulary. Patients already on therapy are typically exempt from new step therapy requirements.

Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters, plan policies, and clinical notes to draft targeted, evidence-backed rebuttals. Their platform helps patients, clinicians, and specialty pharmacies navigate complex prior authorization requirements and appeals processes for specialty medications like Vitrakvi.

For additional support with Humana appeals or complex PA requirements, Counterforce Health's platform can help identify specific denial reasons and draft point-by-point responses aligned with your plan's coverage criteria.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Prior authorization requirements and appeal processes may vary by plan and change over time. Always consult with your healthcare provider and insurance plan for the most current requirements and procedures.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.